ShapeWayTM Metabolic Energizer

Transcription

ShapeWayTM Metabolic Energizer
ShapeWayTM Metabolic Energizer
ShapeWayTM Metabolic Energizer is a proprietary blend of three active
ingredients. The objective of the Metabolic Energizer is that is it may
better help the body to metabolize fat in the bloodstream, essentially
using the fat for increased energy as opposed to storing it in the body. A
double blind, human clinical trial was conducted in 2008 to test the
ingredients used in the ShapeWayTM formula. The study was focused
around the two following ingredients.
Calculis-CQTM is an eXfuze trademarked ingredient which is derived from
cissus quadrangularis, which is harvested from a succulent vine native to
West Africa and Southeast Asia and has been used in traditional African
and Ayurvedic medicine for more than a century. Studies have
examined uses of Calculis-CQTM, including its role in fighting obesity and
symptoms of metabolic syndrome. The unique chemical constituents of
Calculis-CQTM, includes flavonoids as well as many phytochemicals which
have shown promise as powerful and efficient antioxidants. They also
appear to be efficient for lipase and amylase inhibition, thereby possibly
providing a mechanism for weight loss via reduced oxidative stress,
dietary fat, and carbohydrate blocking.
The ShapeWayTM Metabolic Energizer combines Calculis-CQTM and the
eXfuze trademarked Lepticyte-iGTM, which is derived from a plant
belonging to the Irvingiaceae family. The Irvingia Tree, commonly
known as Bush Mango, Dikanut or African Mango, is indigenous to West Africa. Although the flesh of the Irvingia Tree
fruit is widely consumed, its most important part for nutraceutical purposes is the kernel. The high soluble fiber
contained in Lepticyte-iGTM, may affect the lowering of plasma cholesterol, triglycerides, and glucose concentrations.
More importantly, the glycoproteins in the fruit seeds seem to inhibit hydrolase enzymes by blocking the active sites or
altering enzyme configurations. Recent investigation of the amylase inhibitory activity provides a mechanistic hypothesis
for the numerous studies supporting Lepticyte-iGTM anti-diabetic potential. This may occur via its ability to reduce fasting
blood glucose levels. In addition to their anti-diabetic activity, the fruit seeds of the Irvingia Tree have shown promise as
an anti-obesity agent.
The human clinical study results posted in this document are the result of a test primarily designed to test the efficacy of
a combination of these two extraordinary plants in the management of obesity and obesity-related complications in
humans.
DISCLAIMER: None of this information is in any way an attempt to prognosticate, diagnose or prescribe the use of our product as a cure or treatment for any
disease illness or condition. The eXfuze website, its content, such as text and other audio-visual material contained on the site, and any information or material
posted on the eXfuze site by company officers, company employees, independent distributors, other third parties (or forwarded to you by a friend) are provided
for informational purposes only. None of the foregoing is to be construed as a substitute for professional medical advice, examination, diagnosis, or treatment
by a licensed physician or health care professional. As with many nutritional products we issue the same standard precaution that this product should not be
taken by pregnant or lactating women unless recommended by their doctor. Always seek the advice of a physician or other qualified healthcare provider with
any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have
read on the eXfuze website or received from an eXfuze distributor. If you think you may have a medical emergency, call your doctor or 911 immediately. These
statements have not been approved by the FDA.
Page 1
VCN-340.11-v3-SWMECFLYR-USA.enu
*Clinical Data Results:
Percentage of body Weight Lost
Study Group
Placebo
iGTM/CQTM Ingredient Blend
Weight Change (%)
4 Weeks
Gained <1%
Lost 4.02%
8 Weeks
Lost 1.33%
Lost 8.9%
10 Weeks
Lost 2.1%
Lost 11.86%
Fat Reduction (%)
4 Weeks
Lost 2.85%
Lost 9.11%
8 Weeks
Lost 3.33%
Lost 17.19%
10 Weeks
Lost 3.97%
Lost 20.06%
Waist Change (%)
4 Weeks
Lost <1%
Lost 5.77%
8 Weeks
Lost <1%
Lost 7.96%
10 Weeks
Lost 1%
Lost 20.98%
Change (%)
4 Weeks
Down <3.97%
Down 29.21%
8 Weeks
Up 2.64%
Down 41.59%
10 Weeks
Up 2.23%
Down 44.30%
Percentage of body Fat Lost
Study Group
Placebo
iGTM/CQTM Ingredient Blend
Waist Size Change
Study Group
Placebo
iGTM/CQTM Ingredient Blend
Plasma total cholesterol
Study Group
Placebo
iGTM/CQTM Ingredient Blend
*Study Methods: 10 week randomized, double-blind, placebo-controlled, design involving 72 obese or overweight
participants, 45.8% male; 54.2% male, mean age 29.3. Divided into three groups; placebo only, CQ only, and iG/CQ
combination.
Nutritional Information:
Supplement Facts
Other Ingredients:
Rice Flour, Magnesium Stearate, and Vegetable
SERVING SIZE: 2 CAPSULES
Capsule.
AMOUNT PER SERVING CONTAINS A PROPRI*From 100% Irvingia gabonensis IGOB 131® and Cissus quadrangularis CQR-300® proprietary extracts, a registered trademark of Gateway
ETARY BLEND* OF:
Health Alliances, Inc. Fairfield CA. US PATENT 7,537,790 and
TM
TM
Lepticyte-iG 250 mg*, Calculis-CQ 250 mg*, 7,175,859. US and Intl. Patents pending. **ChromeMate® is a
ChromeMate® (Chromium as O-polynicotinate) registered trademark of InterHealth N.I.Manufactured exclusively for eXfuze, LLC:
KEEP IN A COOL DRY PLACE
11780 US Hwy One, Suite 302
2 mg**
KEEP OUT OF THE REACH OF CHILDREN
Palm Beach Gardens, FL 33408
Page 2
VCN-340.11-v3-SWMECFLYR-USA.enu